Dianthus Therapeutics, Inc.
claseprubart
Generalized Myasthenia Gravis
Countdown
908days
Phase 3 readout · ~ Dec 31, 2028 estimated
What's at stake
Phase 3 trial results for claseprubart in Generalized Myasthenia Gravis are due ~ Dec 31, 2028. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· Press release
verified 15h ago
“EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial that will evaluate claseprubart 300mg/2mL S.C. dosed Q2W and Q4W vs. placebo, with top-line results anticipated in 2H’28”